Genmab — December 2018
-
DRd ser ud til at være bedre end DVd i RRMM så hvorfor ikke i 1L ? https://learningcenter.ehaweb.org/eha/2017/22nd/181388/jesus.san-miguel.efficacy.by.cytogenetic.risk.status.for.daratumumab.in.html
-
Han siger vel ikke at DRd bliver standard, men bare godkendt. Selv om han er førende myelomatose-mand i DK er det jo ikke ham der afgør sagen. Det gør Medicinrådet, og har på det seneste vist sig at være ret skrappe. Jvf balladen mellem dette og scleroseforeningen.
-
Griffin hjælper også high risk pts https://www.targetedonc.com/news/voorhees-highlights-encouraging-findings-with-daratumumab-plus-rvd-in-myeloma-
-
Har denne været nævnt. ? Ellers undskyld.
. Daratumumab and donor Lymphocyte Infusion In Treating Participants with Relapsed Acute myeloid Leukemia After Stemm Cell Transplant. - to start december 31 - 2018. https://www.clinicaltrials.gov/ct2/show/study/NCT03537599?term=Darzalex&cond=Aml&rank=2&show_desc=Y#desc -
God morgen

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind